

DAY 1 – November 13

TIME	TOPIC	PRESENTER
9.30-11.00	Update on the ITCC year <i>Chair:</i>	Pamela Kearns
9.30-9.45	ITCC Strategy progress report	Pam Kearns
9.45-10.10	Sponsor Network Committee	Paco Bautista
10.10-10.30	ITCC Industry Strategy	Gilles Vassal
10.30-11.00	ITCC Education Update from research nurse education plans Updates from 2024 Clinical Fellows	Karsten Nysom Tracey Crowe Anne Cvrtak/Elisabeth Salzer
11.00-11.30	Coffee	
11.30-13.30	Research in Progress <i>Chair:</i>	Michel Zwaan
11.30-12.10	Paediatric Bespoke Therapeutic Development Workshops: Progress & Outcomes	Jan Molenaar et al
12.10-12.30	Antibody Drug Conjugates; outputs from the ACCELERATE Paediatric Strategy Forum	Lia Gore
12.30-12.50	ctDNA: what is their role as a biomarker in ITCC clinical trials? (remote)	Dominik Karres
12.50-13.20	How early can we take a new drug into a CYP (regulatory and ethics)?: Panel Discussion	Nick Bird
13.20-14.20	Lunch	
14.20-16.00	Current Challenges in Clinical Trials <i>Chair:</i>	Michela Casanova
14.20-14.40	Changing landscape of cancer in young people: accessing the right treatment?	Nathalie Gaspar
14.40-15.00	Cross Border Access to Clinical Trials: SIOPE/ITCC/PaedCan ERN collaboration	Gilles Vassal /Nicole Scobie
15.00-15.40	Keynote Lecture: Role of NK cells in childhood cancer (remote)	Katy Rezvani
15.40-16.00	Where are we with CAR-T cell trials and solid tumours?	Claudia Rossig
16.00-16.30	Coffee	
16.30-17.40	Clinical Trial Updates <i>Chair:</i>	Henning Klusmann
16.30-16.45	ITCC-098 Brigatinib	Charlotte Rigaud
16.45-17.15	ITCC-057 ESMART (arm O results plus new Q&R arms)	Nicolas Andre/Pablo Berlanga
17.15-17.25	ITCC-104 Hem-iSMART- capivasertib	Andrej Lissat
17.25-17.40	ITCC-110 Epilogue	Cornelis Van Tilburg
17.40	Group picture	
18.00-18.30	General Assembly/Business meeting (<i>closed meeting reserved to member representatives</i>)	
From 19.00	Social Dinner & Party	

DAY 2 – November 14

TIME	TOPIC	PRESENTER
09.00-10.45	Updates on Partnerships <i>Chair:</i>	<i>Andy Pearson</i>
09.00-09.20	Pediatric Neuro-Oncology Consortium (PNOC)	Sabine Mueller
09.20-09.40	COG Pediatric Early Phase-Clinical Trial Network (PEP-CTN)	Beth Fox
09.40-10.00	ACCELERATE	Nicole Scobie
10.00-10.20	CO-ACT; new initiative from ANZCHOG	Maria Kirby
10.20-10.45	Interactions between ITCC, ITCC-P4 and the ITCC PedCan Portal	Gilles Vassal
10.45-11.15	Coffee Break	
11.15-13.00	Clinical Trials Reports and second generation trials <i>Chair:</i>	<i>Karsten Nysom</i>
11.15-11.30	ITCC-076 NIVOALCL	Charlotte Rigaud
11.30-11.45	ITCC-XX LightBeam Trial	Michela Casanova
12.00-12.15	ITCC-105 SACHA-international	Pablo Berlanga
12.15-12.30	ITCC-097 REGO-INTER EWING phase I	Pablo Berlanga
12.30-12.45	ITCC-111 BEACON 2	Lucas Moreno
12.45-13.00	ITCC-072 INFORM 2 NiVent and ITCC-117 VolVin	Cornelis Van Tilburg
13.00-13.15	ITCC-051 BIOMEDE 2.0	Jacques Grill
13.15-14.15	Lunch	
14.15-15.30	Future aspirations for ITCC trials <i>Chair:</i>	<i>Gilles Vassal</i>
14.15-14.45	Patient advocacy engagement in study design and delivery; what does good look like? Presentation and discussion	N.Scobie/A.Burke
14.45-15.00	Report from the Advancing Childhood Cancer Academic-Industry Collaborative Platform Trials Multi-Stakeholder Workshop	Pam Kearns
15.00-15.30	Keynote lecture: The microbiome and its implications cancer immunosurveillance and treatment response	Laurence Zitvogel
15.30-15.40	Wrap Up and Conclusion	Pam Kearns

KEYNOTE LECTURES



Prof. Katy Rezvani, MD, PhD is a professor of medicine at the University of Texas MD Anderson Cancer Center, where she serves as the Vice President & Head, Cell Therapy Institute for Discovery and Innovation, Sally Cooper Murray Chair in Cancer Research, and medical director of the GMP Facility. She leads a research lab with a focus on NK cell biology and developing novel NK cell engineering strategies for cancer, with the aim of translating these discoveries to the clinic. Dr. Rezvani completed her medical training at University College London, England and her PhD at Imperial College London. She completed her training in immunology and transplantation biology at the National Institutes of Health, Bethesda, MD. In addition, she has co-authored over 250 peer-reviewed publications and received multiple prizes and awards, including the American Society of Hematology E. Donnall Thomas award.



Prof. Laurence Zitvogel is a clinical oncologist and immunologist, and a full professor at Paris-Saclay University. After qualifying in medical oncology in 1992, she began her scientific career at the University of Pittsburgh (USA), where she specialised in both translational and fundamental immunology. In 1998, she was appointed Director of Research at Inserm (U1015), and in 2020, became Scientific Director of the Clinicobiome programme at Gustave Roussy. Her work has played a key role in advancing cancer immunology and immunotherapy. With her team, she has pioneered several major concepts, including immunogenic cell death and the impact of the gut microbiota on cancer immunosurveillance and treatment response. She is among the world's most cited scientists, according to Clarivate Analytics, appearing on the Highly Cited Researchers list since 2016. She has an h-index of 173, with over 599 publications listed on PubMed and more than 165,000 citations. She is also the scientific founder of the biotech company everImmune, dedicated to the clinical development of microbiota-based therapies in oncology.